

Molecular characterization in endometrial cancer: progress and prospects

Guest Editor



Andrea Giannini, MD, PhD

Department of Medical and Surgical Sciences and Translational Medicine,
Sapienza University, Rome, Italy

Interests: Gynecological tumors, Surgical and invasive medical procedures,
Gynecologic surgery, Women's health, Obstetrics and gynecology, Gynecologic
cancers, Oncology

Email: andregiannini23@hotmail.it

Endometrial carcinoma (EC) is the most common gynecological malignant disease in high income countries. This tumor is increasingly characterized by molecular pattern for prognosis and selection of treatment, drastically changing the treatment options and response rate for advanced and recurrent endometrial cancer and adding new information to the conventional morphologic features. In view of the important prognostic and therapeutic implications, the 2020 ESGO/ESTRO/ESP guidelines for the EC management defined new prognostic risk groups, integrating molecular markers.

Since the great importance given to this new approach, the aim of this special issue is to focus our research on progress and new frontiers on this topic in the precision medicine era, to improve the management and outcomes of EC patients, considering comorbidities and clinical aspects too. Is the validation of a prognostic model possible?

Key Words: Endometrial cancer (EC); molecular biomarkers; Immune checkpoint inhibitor; precision medicine

Submission Deadline: 31 December 2022

Online Submission System: <https://js.ejgo.net/ch/author/login.aspx>

<https://www.ejgo.net/>